Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.38 |
| ▸ | WNT1 | P04628 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1572819 | 0.91 | EGFR (0.47) | EGFRERBB2TBK1PRKCQWNT1 | |
| SCHEMBL1871547 | 0.91 | EGFR (0.46) | EGFRERBB2GPR119TBK1PRKCQ | |
| SCHEMBL1571689 | 0.84 | EGFR (0.51) | EGFRERBB2GPR119TBK1PRKCQ | |
| SCHEMBL1571697 | 0.83 | EGFR (0.50) | EGFRERBB2GPR119TBK1PRKCQ | |
| SCHEMBL1573239 | 0.81 | EGFR (0.47) | EGFRERBB2TBK1PRKCQWNT1 | |
| SCHEMBL1869714 | 0.80 | EGFR (0.49) | EGFRERBB2GPR119TBK1PRKCQ | |
| SCHEMBL1571703 | 0.76 | IKBKB (0.43) | GPR119TBK1JAK2JAK1TYK2 | |
| SCHEMBL13225893 | 0.76 | EGFR (0.40) | EGFRERBB2TBK1PRKCQDYRK1A | |
| SCHEMBL1571105 | 0.75 | MKNK1 (0.40) | EGFRGPR119TBK1JAK2JAK1 | |
| SCHEMBL1570917 | 0.74 | JAK2 (0.42) | EGFRGPR119TBK1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008079988-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | EGFR 1733/4885ERBB2 1242/4885GPR119 508/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | EGFR 1053/4885ERBB2 1020/4885GPR119 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.